/PRNewswire/ Corza Medical ("Corza"), a leading global manufacturer of innovative surgical technologies, today announced the expansion of its leadership.
717.5
-3.8%
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at
(2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.
(3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
GTCR and Gregory T. Lucier Announce Merger of Surgical Specialties and TachoSil to Create Corza Medical
February 1, 2021 GMT
CHICAGO and WESTWOOD, Mass., Feb. 1, 2021 /PRNewswire/ GTCR, a leading private equity firm, announced today that its management partnership with Gregory T. Lucier, Corza Health, has simultaneously acquired and merged Surgical Specialties Corporation (“Surgical Specialties”) and the TachoSil® Fibrin Sealant Patch (“TachoSil”) to create a new company, Corza Medical. Surgical Specialties is a medical technology company focused on high-performance surgical sutures and ophthalmic knives. TachoSil, previously owned by Takeda Pharmaceutical Company Limited, is a differentiated surgical patch product line used to enable safe and fast bleeding control during surgeries.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Completes Sale of TachoSil® to Corza Health
February 1, 2021 GMT
OSAKA, Japan (BUSINESS WIRE) Feb 1, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil ® Fibrin Sealant Patch (“TachoSil ® ”) to Corza Health, Inc. (“Corza”) for €350 million.
ADVERTISEMENT
TachoSil ® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil®, while Takeda maintains ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing & supply agreement, under which it will continue to exclusively manufacture TachoSil